CD40LG and myeloid sarcoma: Regarding the prevalence of the IgG and IgM antibodies against the viruses analyzed, we did not find any statistically significant difference when we compared treated and untreated MS patients: 86.6% vs. 90.9% for HHV-6A/B IgG, 16.7% vs. 7.5% for HHV-6A/B IgM, 94.6% vs. 94.6% for EBNA-1 IgG, 99.2% vs. 100% for VCA IgG, 61.4% vs. 61.4% for CMV IgG and 6.4% vs. 0% for CMV IgM, respectively.